BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 21294597)

  • 41. Population pharmacokinetic modeling of oral cyclosporin using NONMEM: comparison of absorption pharmacokinetic models and design of a Bayesian estimator.
    Rousseau A; Léger F; Le Meur Y; Saint-Marcoux F; Paintaud G; Buchler M; Marquet P
    Ther Drug Monit; 2004 Feb; 26(1):23-30. PubMed ID: 14749545
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Diabetes mellitus reduces the clearance of atorvastatin lactone: results of a population pharmacokinetic analysis in renal transplant recipients and in vitro studies using human liver microsomes.
    Dostalek M; Sam WJ; Paryani KR; Macwan JS; Gohh RY; Akhlaghi F
    Clin Pharmacokinet; 2012 Sep; 51(9):591-606. PubMed ID: 22775412
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia: a novel once-monthly, long-acting formulation of an atypical antipsychotic.
    Samtani MN; Vermeulen A; Stuyckens K
    Clin Pharmacokinet; 2009; 48(9):585-600. PubMed ID: 19725593
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacokinetics of voriconazole after single dose intravenous and oral administration to alpacas.
    Chan HM; Duran SH; Walz PH; Ravis WR
    J Vet Pharmacol Ther; 2009 Jun; 32(3):235-40. PubMed ID: 19646087
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacokinetics and safety of 14 days intravenous voriconazole in allogeneic haematopoietic stem cell transplant recipients.
    Brüggemann RJ; Blijlevens NM; Burger DM; Franke B; Troke PF; Donnelly JP
    J Antimicrob Chemother; 2010 Jan; 65(1):107-13. PubMed ID: 19933691
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety.
    Purkins L; Wood N; Greenhalgh K; Allen MJ; Oliver SD
    Br J Clin Pharmacol; 2003 Dec; 56 Suppl 1(Suppl 1):10-6. PubMed ID: 14616408
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Toward better outcomes with tacrolimus therapy: population pharmacokinetics and individualized dosage prediction in adult liver transplantation.
    Staatz CE; Willis C; Taylor PJ; Lynch SV; Tett SE
    Liver Transpl; 2003 Feb; 9(2):130-7. PubMed ID: 12548506
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype.
    Scholz I; Oberwittler H; Riedel KD; Burhenne J; Weiss J; Haefeli WE; Mikus G
    Br J Clin Pharmacol; 2009 Dec; 68(6):906-15. PubMed ID: 20002085
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacokinetics and tolerability of voriconazole and a combination oral contraceptive co-administered in healthy female subjects.
    Andrews E; Damle BD; Fang A; Foster G; Crownover P; LaBadie R; Glue P
    Br J Clin Pharmacol; 2008 Apr; 65(4):531-9. PubMed ID: 18294327
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacokinetics, safety and tolerance of voriconazole in renally impaired subjects: two prospective, multicentre, open-label, parallel-group volunteer studies.
    Abel S; Allan R; Gandelman K; Tomaszewski K; Webb DJ; Wood ND
    Clin Drug Investig; 2008; 28(7):409-20. PubMed ID: 18544001
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Voriconazole pharmacokinetics and safety in immunocompromised children compared to adult patients.
    Michael C; Bierbach U; Frenzel K; Lange T; Basara N; Niederwieser D; Mauz-Körholz C; Preiss R
    Antimicrob Agents Chemother; 2010 Aug; 54(8):3225-32. PubMed ID: 20547816
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis.
    Zhou H; Mayer PR; Wajdula J; Fatenejad S
    J Clin Pharmacol; 2004 Nov; 44(11):1235-43. PubMed ID: 15496641
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A single Bayesian estimator for iohexol clearance estimation in ICU, liver failure and renal transplant patients.
    Destere A; Salmon Gandonnière C; Åsberg A; Loustaud-Ratti V; Carrier P; Ehrmann S; Barin-Le Guellec C; Marquet P; Woillard JB
    Br J Clin Pharmacol; 2022 Jun; 88(6):2793-2801. PubMed ID: 34951499
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Population Pharmacokinetics of Voriconazole in Chinese Patients with Hematopoietic Stem Cell Transplantation.
    Chen C; Yang T; Li X; Ma L; Liu Y; Zhou Y; Ren H; Cui Y
    Eur J Drug Metab Pharmacokinet; 2019 Oct; 44(5):659-668. PubMed ID: 31041728
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impact of CYP2C19 Genotype and Liver Function on Voriconazole Pharmacokinetics in Renal Transplant Recipients.
    Li ZW; Peng FH; Yan M; Liang W; Liu XL; Wu YQ; Lin XB; Tan SL; Wang F; Xu P; Fang PF; Liu YP; Xiang DX; Zhang BK
    Ther Drug Monit; 2017 Aug; 39(4):422-428. PubMed ID: 28604474
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentrations in stable renal transplant patients.
    Le Guellec C; Bourgoin H; Büchler M; Le Meur Y; Lebranchu Y; Marquet P; Paintaud G
    Clin Pharmacokinet; 2004; 43(4):253-66. PubMed ID: 15005639
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study.
    Lazarus HM; Blumer JL; Yanovich S; Schlamm H; Romero A
    J Clin Pharmacol; 2002 Apr; 42(4):395-402. PubMed ID: 11936564
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evaluation of limited sampling methods for estimation of tacrolimus exposure in adult kidney transplant recipients.
    Barraclough KA; Isbel NM; Kirkpatrick CM; Lee KJ; Taylor PJ; Johnson DW; Campbell SB; Leary DR; Staatz CE
    Br J Clin Pharmacol; 2011 Feb; 71(2):207-23. PubMed ID: 21219401
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A limited sampling strategy to estimate exposure of once-daily modified release tacrolimus in renal transplant recipients using linear regression analysis and comparison with Bayesian population pharmacokinetics in different cohorts.
    Stifft F; Vandermeer F; Neef C; van Kuijk S; Christiaans MHL
    Eur J Clin Pharmacol; 2020 May; 76(5):685-693. PubMed ID: 32020321
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Model-Informed Precision Dosing of Everolimus: External Validation in Adult Renal Transplant Recipients.
    Zwart TC; Moes DJAR; van der Boog PJM; van Erp NP; de Fijter JW; Guchelaar HJ; Keizer RJ; Ter Heine R
    Clin Pharmacokinet; 2021 Feb; 60(2):191-203. PubMed ID: 32720301
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.